Interview with Jean-Pierre Delwart, Chief Executive Officer, Eurogentec Belgium
Mr Delwart, you have been acting CEO of EuroGenTec for an impressive 19 years. During your tenure, what would you say has been the single most important change in the…
Address: Rue du Bois Saint Jean, 5, 4102 Seraing,Belgium
Tel: +32 4 372 74 00
Web: http://www.eurogentec.com/eu-home.html
Eurogentec S.A., part of Kaneka Corporation, is a leading global supplier of innovative reagents, kits, specialty products and custom services. Through its three inter-related business units (BU), the company provides high quality products to scientists involved in the life science, biotechnology, diagnostic and pharmaceutical markets. Eurogentec is fully ISO 9001, ISO 13485 certified, cGMP accredited by the Belgian Ministry of Health and approved by the US FDA for the commercial manufacturing of a biologic for the US market.
The Life Science Research BU is specialized in innovative solutions in Genomics and Proteomics. Expert in small and large-scale synthesis, Eurogentec proposes a wide range of reagents, kits and consumables for Life Science applications such as Custom Oligonucleotides, high performance PCR/qPCR Kits & Reagents (including high pure Diamond Taq® DNA Polymerases), catalogue dyes, peptides & antibodies. Eurogentec is also specialist in the design and synthesis of custom peptides and production of custom antibodies (including a 28-day Speedy protocol) as well as producing pre-dispensed assays in a GMP environment.
The In Vitro Diagnostics BU provides technical and project support for contract manufacturing of GMP oligonucleotides and Taq DNA polymerases for use in Molecular Diagnostic applications. As a certified ISO 13485 and GMP compliant manufacturer, our manufacturing processes take place in classified clean rooms with controlled processes and full traceability. Our production facilities in Belgium and US enable high quality materials for the in vitro Diagnostic community.
The GMP BioManufacturing BU is a full-service Contract Manufacturing Organization (CMO) and offers significant know-how in process development, technology transfer, formulation, scale-up and manufacturing of GMP proteins, protein conjugates, plasmids and bacterial vaccines for pre-clinical, clinical and commercial uses, all according to FDA and EMA requirements. Experts in microbial production (E. coli, P. pastoris, etc), Eurogentec offers various development strategies based on protein refolding, periplasmic expression, and protein expression by secretion. As a one-stop shop, Eurogentec provides a complete gene to injectable service offering.
Mr Delwart, you have been acting CEO of EuroGenTec for an impressive 19 years. During your tenure, what would you say has been the single most important change in the…
Professor Sylvie Rottey, president of the Belgian Society of Medical Oncology (BSMO) outlines the state of cancer care in Belgium, the country’s positioning in clinical trials for medical oncology, and…
Erik Present is president of Healixia, a newly formed association for medical professionals in Belgium. Present introduces the mission and purpose of Healixia, the work it is currently undertaking in…
Sabena Solomon, general manager of GSK Benelux, speaks about her first impressions of the Belgium market, having come from GSK Finland, and her initial priorities for leading the affiliate. Solomon…
Karel Van De Sompel, country manager of Pfizer in Belgium and Luxembourg and chairman of Pharma.be, highlights the key changes he sees in today’s pharma market which revolve around the…
Professor Stéphane De Wit, head of the Department of Infectious Diseases at St Pierre University Hospital outlines Belgium’s approach to tackling HIV treatment, how academia-industry collaboration is progressing in the…
In 2020 PharmaBoardroom sat down with several key stakeholders in Belgian pharma to discuss company strategy, the Belgian healthcare landscape at large, and the country’s role within the wider European…
Francis Arickx, country coordinator of Belgium for the Beneluxa Initiative, introduces the project and its mission to help shape a unified healthcare policy approach between its member countries through activities…
Ian Wilders of Spain-headquartered micro-immunotherapy specialist Labo’Life discusses the strategic importance of Belgium to the company as the country in which micro-immunotherapy was discovered and where regulation conducive to the…
Luc Van Gorp of the Christian Mutuality Health Insurance Fund, Belgium’s largest health insurance fund, explains the organisation’s role within the Belgian healthcare system, how increased consolidation in recent years…
Dirk Reyn of Flanders.bio highlights what the Flanders region has to offer the life sciences and biotech industries in terms of research infrastructure, funding opportunities, and inter-industry collaboration. In…
Anne-Laure Dreno, country president of AstraZeneca in Belgium, elaborates on the significant position Belgium and the local affiliate have for the group as a frontrunner in innovative areas such as…
Roxana Botea, country manager of ViiV Healthcare in Belgium and Luxembourg, shares her experience joining the organization after a long career experience with GSK and her priorities as a first-time…
See our Cookie Privacy Policy Here
